<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38233059</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives.</ArticleTitle><Pagination><StartPage>e076992</StartPage><MedlinePgn>e076992</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e076992</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-076992</ELocationID><Abstract><AbstractText Label="OBJECTIVES">There is limited qualitative research on patients' experiences with long COVID-19, and how specific symptoms impact their daily lives. The study aimed to understand patients' lived experiences of long COVID-19 and to develop a conceptual model representing the symptoms and their impact on overall quality of life.</AbstractText><AbstractText Label="SETTING">Qualitative study consisting of a comprehensive literature review, and in-depth clinician and patient semistructured interviews.</AbstractText><AbstractText Label="PARTICIPANTS">Forty-one adult patients with long COVID-19, of whom 18 (44%) were recruited through Regeneron Pharmaceuticals's clinical trials and 23 (56%) through recruitment agencies; 85.4% were female and 73.2% were White. Five independent clinicians treating patients with long COVID-19 were interviewed. Concept saturation was also assessed.</AbstractText><AbstractText Label="PRIMARY AND SECONDARY OUTCOMES">Interview transcripts were analysed thematically to identify concepts of interest spontaneously mentioned by patients, including symptoms and their impacts on daily life, to guide the development of the conceptual model.</AbstractText><AbstractText Label="RESULTS">Findings from the literature review and clinician and patient interviews resulted in the development of a conceptual model comprising two overarching domains: symptoms (upper respiratory tract, lower respiratory tract, smell and taste, systemic, gastrointestinal, neurocognitive and other) and impacts (activities of daily living, instrumental activities of daily living, physical impacts, emotional, social/leisure activities and professional impacts). Saturation was achieved for the reported impacts. The symptoms reported were heterogenic; neurocognitive symptoms, such as numbness, ringing in ears, haziness, confusion, forgetfulness/memory problems, brain fog, concentration, difficulties finding the right word and challenges with fine motor skills, were particularly pertinent for several months.</AbstractText><AbstractText Label="CONCLUSION">The conceptual model, developed based on patient experience data of long COVID-19, highlighted numerous symptoms that impact patients' physical and mental well-being, and suggests humanistic unmet needs. Prospective real-world studies are warranted to understand the pattern of long COVID-19 experienced in larger samples over longer periods of time.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rofail</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2125-4734</Identifier><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA diana.rofail@regeneron.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somersan-Karakaya</LastName><ForeName>Selin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Julia Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Modus Outcomes, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przydzial</LastName><ForeName>Krystian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Modus Outcomes, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6138-7021</Identifier><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podolanczuk</LastName><ForeName>Anna J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mylonakis</LastName><ForeName>Eleftherios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geba</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><Identifier Source="ORCID">0000-0001-8936-748X</Identifier><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">INFECTIOUS DISEASES</Keyword><Keyword MajorTopicYN="N">Patient Reported Outcome Measures</Keyword></KeywordList><CoiStatement>Competing interests: DR is a Regeneron Pharmaceuticals, Inc. employee/stockholder and former Roche employee, and current stockholder. SS-K, YZ, MH, TDN and GPG are employees/stockholders at Regeneron Pharmaceuticals, Inc. JYC and KP are employees of Modus Outcomes, and consulted for Regeneron Pharmaceuticals, Inc. AJP reported receiving personal fees from Regeneron Pharmaceuticals, Inc. during the conduct of the study, personal fees from Imvaria, Boehringer Ingelheim, EBSCO/Dynamed and Roche outside the submitted work. EM reports payments to his institution received from SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Pfizer, Chemic Labs/KODA Therapeutics, Cidara and Leidos Biomedical Research/NCI; and reports Advisory board: Basilea and grants from NIH/NIAID, NIH/NIGMS and BARDA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>18</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>17</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38233059</ArticleId><ArticleId IdType="pmc">PMC10806796</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-076992</ArticleId><ArticleId IdType="pii">bmjopen-2023-076992</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention . Long COVID or post-COVID conditions. Available: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html [Accessed 24 Sep 2022].</Citation></Reference><Reference><Citation>Alghamdi F, Owen R, Ashton REM, et al. . Post-acute COVID syndrome (long COVID): what should radiographers know and the potential impact for imaging services. Radiography (Lond) 2022;28 Suppl 1:S93&#x2013;9. 10.1016/j.radi.2022.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radi.2022.08.009</ArticleId><ArticleId IdType="pmc">PMC9468096</ArticleId><ArticleId IdType="pubmed">36109264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierle DM, Aakre CA, Grach SL, et al. . Central sensitization phenotypes in post acute sequelae of SARS-Cov-2 infection (PASC): defining the post COVID syndrome. J Prim Care Community Health 2021;12:21501327211030826. 10.1177/21501327211030826</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501327211030826</ArticleId><ArticleId IdType="pmc">PMC8267019</ArticleId><ArticleId IdType="pubmed">34231404</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr 2021;15:869&#x2013;75. 10.1016/j.dsx.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020. Available: https://www.nice.org.uk/guidance/ng188 [Accessed 24 Sep 2022].</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Coronavirus disease (COVID-19): post COVID-19 condition. 2021. Available: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition [Accessed 26 Sep 2022].</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021;4:e210830. 10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al. . Characterising long COVID: a living systematic review. BMJ Glob Health 2021;6:e005427. 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Caz&#xe9; ABC, Cerqueira-Silva T, Bomfim AP, et al. . Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group. medRxiv 2022. 10.1101/2022.09.15.22279958</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.15.22279958</ArticleId><ArticleId IdType="pmc">PMC10173895</ArticleId><ArticleId IdType="pubmed">37166260</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022;28:1706&#x2013;14. 10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. . Distinguishing features of long COVID identified through immune profiling. medRxiv 2022. 10.1101/2022.08.09.22278592</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, et al. . Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021;18:e1003773. 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo SM, Liu TC, Motwani Y, et al. . Factors associated with post-acute sequelae of SARS-Cov-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med 2022;37:1988&#x2013;95. 10.1007/s11606-022-07523-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07523-3</ArticleId><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med 2023;29:2347&#x2013;57. 10.1038/s41591-023-02521-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02521-2</ArticleId><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, et al. . Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS One 2021;16:e0254523. 10.1371/journal.pone.0254523</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum 2022;3:e221809. 10.1001/jamahealthforum.2022.1809</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM, Summers LH. The COVID-19 pandemic and the $16 trillion virus. JAMA 2020;324:1495&#x2013;6. 10.1001/jama.2020.19759</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19759</ArticleId><ArticleId IdType="pmc">PMC7604733</ArticleId><ArticleId IdType="pubmed">33044484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S, Miyazato Y, Terada M, et al. . Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients. Health Qual Life Outcomes 2022;20:125. 10.1186/s12955-022-02033-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-022-02033-6</ArticleId><ArticleId IdType="pmc">PMC9388960</ArticleId><ArticleId IdType="pubmed">35986269</ArticleId></ArticleIdList></Reference><Reference><Citation>Macpherson K, Cooper K, Harbour J, et al. . Experiences of living with long COVID and of accessing healthcare services: a qualitative systematic review. BMJ Open 2022;12:e050979. 10.1136/bmjopen-2021-050979</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-050979</ArticleId><ArticleId IdType="pmc">PMC8753091</ArticleId><ArticleId IdType="pubmed">35017239</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . Caring for people with post-COVID conditions. Available: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/care-post-covid.html [Accessed 02 Oct 2022].</Citation></Reference><Reference><Citation>Wong AW, Shah AS, Johnston JC, et al. . Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J 2020;56:2003276. 10.1183/13993003.03276-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03276-2020</ArticleId><ArticleId IdType="pmc">PMC7530908</ArticleId><ArticleId IdType="pubmed">33008936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rofail D, McGale N, Podolanczuk AJ, et al. . Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients. BMJ Open 2022;12:e055989. 10.1136/bmjopen-2021-055989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-055989</ArticleId><ArticleId IdType="pmc">PMC9062460</ArticleId><ArticleId IdType="pubmed">35501077</ArticleId></ArticleIdList></Reference><Reference><Citation>Somersan-Karakaya S, Mylonakis E, Menon VP, et al. . Casirivimab and Imdevimab for the treatment of hospitalized patients with COVID-19. J Infect Dis 2022;227:23&#x2013;34. 10.1093/infdis/jiac320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac320</ArticleId><ArticleId IdType="pmc">PMC9384575</ArticleId><ArticleId IdType="pubmed">35895508</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al. . REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med 2021;385:e81. 10.1056/NEJMoa2108163</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108163</ArticleId><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144. 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyrick J. What is good qualitative research? A first step towards a comprehensive approach to judging rigour/quality. J Health Psychol 2006;11:799&#x2013;808. 10.1177/1359105306066643</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1359105306066643</ArticleId><ArticleId IdType="pubmed">16908474</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse JM. The significance of saturation. Qual Health Res 1995;5:147&#x2013;9. 10.1177/104973239500500201</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/104973239500500201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman M, Burke L, Erickson P, et al. . Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health 2009;12:1075&#x2013;83. 10.1111/j.1524-4733.2009.00603.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2009.00603.x</ArticleId><ArticleId IdType="pubmed">19804437</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics 2008;26:363&#x2013;70. 10.2165/00019053-200826050-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200826050-00002</ArticleId><ArticleId IdType="pubmed">18429654</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration . Patient-reported outcome measures: use in medical product development to support labeling claims (guidance for industry). 2009. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims [Accessed 26 Sep 2022].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1629006</ArticleId><ArticleId IdType="pubmed">17034633</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration . Patient-focused drug development: methods to identify what is important to patients. 2022. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients [Accessed 27 Sep 2022].</Citation></Reference><Reference><Citation>Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77&#x2013;101. 10.1191/1478088706qp063oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1478088706qp063oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling A. Research methods in health: investigating health and health services. 3rd ed. Maidenhead: Open University Press, 2009.</Citation></Reference><Reference><Citation>Bryman A, Burgess B. Analyzing qualitative data. New York: Routledge, 2002.</Citation></Reference><Reference><Citation>Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval 2006;27:237&#x2013;46. 10.1177/1098214005283748</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1098214005283748</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrocini G, Cacciapuoti S, Monfrecola G. A qualitative investigation of the impact of Acne on health-related quality of life (HRQL): development of a conceptual model. Dermatol Ther (Heidelb) 2018;8:85&#x2013;99. 10.1007/s13555-018-0224-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13555-018-0224-7</ArticleId><ArticleId IdType="pmc">PMC5825329</ArticleId><ArticleId IdType="pubmed">29435857</ArticleId></ArticleIdList></Reference><Reference><Citation>Klassen AF, Pusic AL, Scott A, et al. . Satisfaction and quality of life in women who undergo breast surgery: a qualitative study. BMC Womens Health 2009;9:11. 10.1186/1472-6874-9-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6874-9-11</ArticleId><ArticleId IdType="pmc">PMC2685365</ArticleId><ArticleId IdType="pubmed">19409078</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration . CDER patient-focused drug development. 2023. Available: https://content.govdelivery.com/accounts/USFDA/bulletins/34aabd8 [Accessed 30 Mar 2023].</Citation></Reference><Reference><Citation>Han Q, Zheng B, Daines L, et al. . Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens 2022;11:269. 10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SE, Haroon S, Subramanian A, et al. . Development and validation of the symptom burden questionnaire for long Covid (SBQ-LC): Rasch analysis. BMJ 2022;377:e070230. 10.1136/bmj-2022-070230</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070230</ArticleId><ArticleId IdType="pmc">PMC9043395</ArticleId><ArticleId IdType="pubmed">35477524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Preston N, Parkin A, et al. . The modified COVID-19 yorkshire rehabilitation scale (C19-YRSm) patient-reported outcome measure for long Covid or post-COVID-19 syndrome. J Med Virol 2022;94:4253&#x2013;64. 10.1002/jmv.27878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27878</ArticleId><ArticleId IdType="pmc">PMC9348420</ArticleId><ArticleId IdType="pubmed">35603810</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala R. Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19Qol) instrument. Health Qual Life Outcomes 2021;19:229. 10.1186/s12955-021-01862-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-021-01862-1</ArticleId><ArticleId IdType="pmc">PMC8477362</ArticleId><ArticleId IdType="pubmed">34583690</ArticleId></ArticleIdList></Reference><Reference><Citation>Samper-Pardo M, Oliv&#xe1;n-Bl&#xe1;zquez B, Magall&#xf3;n-Botaya R, et al. . The emotional well-being of long COVID patients in relation to their symptoms, social support and stigmatization in social and health services: a qualitative study. BMC Psychiatry 2023;23:68. 10.1186/s12888-022-04497-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-022-04497-8</ArticleId><ArticleId IdType="pmc">PMC9875186</ArticleId><ArticleId IdType="pubmed">36698111</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Molina A, Garc&#xed;a-Carmona S, Espi&#xf1;a-Bou M, et al. . Neuropsychological rehabilitation for post-COVID-19 syndrome: results of a clinical programme and six-month follow up. Neurologia (Engl Ed) 2022. 10.1016/j.nrleng.2022.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrleng.2022.06.007</ArticleId><ArticleId IdType="pmc">PMC9476330</ArticleId><ArticleId IdType="pubmed">36116770</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, et al. . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 2022;13:1957. 10.1038/s41467-022-29521-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>